Advertise with us
[May 12, 2014]
Taiho Oncology Marks Transition to a Commercial Entity with Key Management Appointment [Global Data Point]
(Global Data Point Via Acquire Media NewsEdge) "Taiho Oncology has been making significant changes to its operations in preparation for the potential commercialization of our lead product, TAS-102, most importantly the appointment of Tim Whitten as our Chief Commercial Officer," said Eric Benn, President and CEO of Taiho Oncology, Inc. "Tim's extensive commercial experience, which includes having launched the highly successful chemotherapy, TAXOL®*, as well as other oncology compounds, makes him particularly well suited to build our commercial organization in the USA and a critical addition to our executive leadership team. Over the past 12 years, Taiho Oncology has built a world class clinical development organization supporting the regional and global development of Taiho's exciting pipeline of compounds. As we prepare for this next important chapter in Taiho's history, we are dedicated to hiring the best talent the industry has to offer and allocating the resources necessary to achieve this same high standard with our commercial organizations as our globalization extends to the major western markets of the United States and Europe." Prior to joining Taiho Oncology, Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, US Oncology and Immunology, and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, he has led several product launches including the successful introduction of TAXOL in the United States. Mr. Whitten was previously employed by Pharmacyclics, where he served in various roles, including Senior Vice President Marketing %7E Sales and Business Development. From 2006 to 2012, he served as President and CEO of Transave/Insmed. During this time he guided the company's lead product from preclinical development to a global Phase III program. In 2010, he took Transave, a private venture capital backed company, into the public marketplace via a merger with Insmed, a company traded on the NASDAQ.
I'm excited about the opportunity that TAS-102 represents for Taiho Oncology," said Mr. Whitten. "We plan to build a strong, patient-centered commercial organization around TAS-102 and our promising oral oncology pipeline." Taiho Oncology, formerly Taiho Pharma USA, Inc., today also announced that it has launched a new website that will showcase its oncology pipeline and provide a detailed overview of its vision and goals.
(c) 2014 GlobalData Provided by Syndigate.info, an Albawaba.com company
Back To NFVZone's Homepage